ibrx stock price: ImmunityBio (IBRX) — Stock Price
IBRX (ImmunityBio, Inc.) — Stock Price
ibrx stock price refers to the market quotation for ImmunityBio, Inc. common shares (ticker IBRX) on the NASDAQ. This article documents how the ibrx stock price is quoted and tracked, the primary metrics and sources to monitor, and the main clinical, financial and market factors that drive movements in ImmunityBio’s share price. Readers will learn where to check real-time quotes, how to interpret key market indicators, and which corporate events historically correlate with price moves. For active monitoring and trading, consider Bitget’s market pages and Bitget Wallet for custody and order execution.
Company overview
ImmunityBio, Inc. is a U.S.-based biotechnology company focused on developing immunotherapies for oncology and infectious diseases. The firm is best known for its lead immunotherapy program branded as Anktiva (nogapendekin alfa inbakicept), positioned for non-muscle-invasive bladder cancer (NMIBC) treatment and other indications. As a clinical-stage / commercial biotech, ImmunityBio combines trial-stage programs with early commercial revenue from Anktiva in select markets.
Understanding ImmunityBio’s business model is essential for interpreting the ibrx stock price: clinical trial readouts, regulatory milestones, product revenue and enrollment progress in registrational trials are high-impact events for investor expectations in this sector.
Ticker and market listing
- Trading symbol: IBRX
- Exchange: NASDAQ
- Trading currency: United States dollars (USD)
- Primary market hours: regular NASDAQ session (U.S. market hours)
- Pre-market and after-hours trading: available through extended-hours sessions on many trading platforms
When discussing the ibrx stock price, note whether the quote is from regular session trading or from pre-/after-hours; extended-hours executions can differ materially from the consolidated regular-session price due to lower liquidity and wider spreads.
Real-time quotes and market data
Intraday and after-hours pricing
Real-time displays for the ibrx stock price typically include the last trade price, bid and ask quotes, trade size, cumulative intraday volume and time stamp. After-hours (post-market) and pre-market quotes are shown separately by most market-data providers; those extended-hours quotes reflect trades executed outside the primary NASDAQ session and can update the displayed ibrx stock price before the next regular session.
Platforms and broker interfaces often present: last trade, trade time, bid/ask and level-2 depth (where available), as well as indicators such as percentage change and intraday high/low. Bitget’s market pages provide live market data for equities alongside educational tools for new users.
Key market metrics
Key market metrics to check when monitoring the ibrx stock price include:
- Market capitalization: the company’s share price multiplied by shares outstanding; a core indication of company size. Monitor market cap shifts as the ibrx stock price changes.
- Shares outstanding and float: total shares issued and shares available for public trading. Float helps explain how sensitive the ibrx stock price may be to demand/supply imbalances.
- Average daily volume: liquidity proxy; higher average volume generally enables tighter bid-ask spreads when trading IBRX.
- 52-week high / 52-week low: context for current levels of the ibrx stock price.
- Common ratios: price-to-earnings (P/E) when earnings exist, but many clinical-stage biotechs will have negative or non-applicable P/E; other ratios and multiples (EV/Revenue, revenue growth rates) may be used instead.
As of Jan. 20, 2026, according to Benzinga, ImmunityBio’s intraday activity showed session volume far above average, and the ibrx stock price was trading near a new 52-week high during a short-term surge tied to fresh regulatory feedback and positive revenue and trial updates.
Data sources and delays
Not all quote displays are identical. Differences include:
- Real-time feeds: some platforms provide true real-time quotes sourced directly from the exchange or from consolidated tape services.
- Delayed feeds: many public or free data sources show a 1-minute (or longer) delay on equity quotes.
- Consolidated tape vs. direct exchange feeds: consolidated tape aggregates trades across venues; proprietary exchange feeds may differ slightly in latency.
Primary public sources for the ibrx stock price include NASDAQ’s market pages, market-data sites like MarketWatch and CNBC, investor platforms such as Robinhood, research portals like Seeking Alpha, and community feeds such as StockTwits. For execution and the most timely tradeable price, use your broker’s live market feed or Bitget’s market interface.
Historical price performance
Price history and charts
Historical charts for the ibrx stock price are available in multiple time frames: intraday (minutes), daily, weekly, monthly and multi-year. Useful measures and overlays include:
- Year-to-date (YTD), 1-year, 3-year and 5-year percentage performance to understand momentum and longer-term trends for the ibrx stock price.
- Trend lines, moving averages (e.g., 50-day and 200-day), and technical indicators to visualize support/resistance and trend changes.
- Volume profile alongside price to identify conviction behind moves in the ibrx stock price.
Interpretation tip: a sharp spike in the ibrx stock price accompanied by volume far above average often indicates a fundamental news event (trial data, regulatory update, earnings), whereas low-volume moves can be less reliable.
Intrinsic events and price impacts (timeline)
Biotech stocks like ImmunityBio commonly experience large single-day or multi-day moves in the ibrx stock price following binary or high-importance events. Typical event categories and effects:
- Regulatory meetings and decisions (FDA Type A/B/C meetings, sBLA/BLA acceptances): positive regulatory feedback or approvals can lift the ibrx stock price materially; requests for more data or clinical trials can depress it.
- Clinical trial readouts and peer-reviewed publications: favorable efficacy/survival data or safety profiles can drive the ibrx stock price higher; negative readouts can cause sharp declines.
- Earnings and revenue disclosures: beats or guidance upgrades generally help the ibrx stock price; missed revenue or downward guidance can weigh on the price.
- Corporate developments: strategic partnerships, licensing deals, manufacturing updates, or changes in executive leadership may influence sentiment and the ibrx stock price.
As an example of recent impact: As of Jan. 20, 2026, according to Benzinga, ImmunityBio disclosed FDA feedback following a Type B meeting related to a supplemental biologics license application (sBLA) for Anktiva in papillary NMIBC. The discussion indicated the company planned to submit additional information to the FDA within 30 days and that a new clinical trial was not required. The announcement was followed by a sharp intraday rise in the ibrx stock price and a session volume spike well above the historical average.
Financial results and fundamental drivers
Revenue, earnings and guidance
Reported revenue and any management guidance are immediate fundamental drivers of the ibrx stock price. ImmunityBio has started to generate product revenue from Anktiva; public disclosure of preliminary net product revenue and quarter-over-quarter growth rates provide tangible metrics investors use to value the company relative to growth expectations.
- As reported by Benzinga, ImmunityBio announced preliminary net product revenue for Anktiva of approximately $113 million for fiscal 2025, a year-over-year increase of about 700% (company statement, referenced in media coverage). For the fourth quarter of 2025, reported revenue was about $38.3 million, representing sequential and year-over-year growth. Announcements like these can reset expectations and influence the ibrx stock price.
Note: many biotech companies remain loss-making while investing heavily in R&D; therefore, investors often weigh revenue trends alongside cash burn and trial milestones rather than relying solely on EPS metrics.
Balance sheet and cash position
A biotech’s balance sheet—cash on hand, debt levels, and access to capital—affects the perceived runway and potential dilution risk. For the ibrx stock price, important balance-sheet items include:
- Cash and equivalents: determines how long the company can fund trials and commercialization without issuing new equity.
- Debt: interest obligations and covenants can affect near-term financial flexibility.
- Potential dilution: equity raises (secondary offerings) can dilute existing shareholders and press the ibrx stock price downward around the offering period.
Investors tracking the ibrx stock price should monitor quarterly filings and company guidance on cash runway and potential financing plans.
Clinical, regulatory and commercial catalysts
Major development catalysts for ImmunityBio that historically and prospectively influence the ibrx stock price include:
- FDA interactions and decisions: meeting outcomes (Type A/B/C), complete response letters, or approvals for new indications are high-impact.
- Trial enrollment milestones and readouts: progress in registrational trials such as QUILT-2.005 (BCG-naïve NMIBC) and QUILT-3.032 (papillary NMIBC) is material to valuation and the ibrx stock price.
- Published clinical results: peer-reviewed publications (for example, a Journal of Urology paper reporting trial outcomes) provide credibility and can shift investor sentiment.
- Commercial adoption metrics: sales growth for Anktiva, reimbursement decisions, and regional approvals.
Example from recent reporting: the company presented updated data from the QUILT-3.032 Phase 2/3 trial showing strong multi-year outcomes—disease-specific survival ~96% at 36 months and cystectomy avoidance rates of 92% at one year and 82% at three years. Such results, and a plan to submit additional material to the FDA without initiating a new trial, were linked to a notable increase in the ibrx stock price on the disclosure date (see Benzinga coverage, Jan. 20, 2026).
Analyst coverage and market sentiment
Sell-side analysts and independent research providers issue ratings, price targets and research notes that can influence short- and medium-term moves in the ibrx stock price. Common analyst actions include: initiating coverage, raising/lowering price targets, and changing recommendations (Buy/Hold/Sell or equivalents).
Examples of analyst commentary observed in recent coverage include Piper Sandler maintaining an Overweight rating and raising a price target, and D. Boral Capital maintaining a Buy rating with a higher target. Analyst revisions and consensus price-target updates are often reported on market sites and can be correlated with shifts in the ibrx stock price.
For sentiment gauges, investors also look at social chatter (e.g., StockTwits), momentum indicators such as RSI, and model-driven rankings. As of Jan. 20, 2026, Benzinga noted elevated RSI values for ImmunityBio, highlighting potential short-term overbought conditions even amid a rapid price rise.
Note: analyst views are informational; they do not replace a company’s filings or official disclosures.
Ownership, short interest and institutional activity
Institutional holdings, insider ownership and short interest data provide context for potential supply/demand dynamics behind the ibrx stock price.
- Institutional holders: large funds and asset managers may own significant positions; quarterly 13F filings and other disclosures reveal shifts in institutional interest.
- Insider ownership and trades: insider purchases or sales reported in SEC forms can signal management’s conviction or liquidity needs.
- Short interest: high short interest can increase volatility and raise the probability of rapid upward moves (short squeezes) if unexpected positive news hits; conversely, low short interest may reduce such pressure.
Regularly checking updated filings and published holder lists helps explain episodic moves in the ibrx stock price.
Trading instruments and liquidity
The primary instrument for exposure is the common equity (IBRX). Depending on market structure and platform support, additional instruments include:
- Options: where available, options contracts provide leverage and hedging; options liquidity is tied to equity liquidity and implied volatility.
- ADRs or foreign listings: ImmunityBio is listed on NASDAQ in USD; cross-listings are uncommon for small-cap biotechs.
Liquidity considerations: average daily volume and spread sizes influence the cost of trading the ibrx stock price. Very high intraday volume can compress spreads and facilitate execution, while low-volume sessions may produce wide spreads and price gaps.
For trade execution and custody needs, Bitget offers market access and Bitget Wallet for secure storage when trading or holding positions.
Risks and valuation considerations
Biotech-specific risks that can affect the ibrx stock price include:
- Clinical and regulatory risk: failed trials or regulatory denials are binary negative events.
- Commercial adoption and reimbursement risk: even with approvals, uptake depends on reimbursement decisions and physician adoption.
- Financing and dilution risk: capital raises can dilute existing shareholders and impact the ibrx stock price.
- Market volatility and sector rotation: macro and sector-level flows can move the ibrx stock price irrespective of company-specific fundamentals.
Valuation approaches commonly applied to biotechs:
- Risk-adjusted net present value (rNPV) models that discount future potential product cash flows by clinical and regulatory probabilities.
- Comparable analysis using revenue multiples (EV/Revenue) against peers when product revenue exists.
- Scenario-based valuation reflecting best-, base- and worst-case clinical outcomes.
All valuation approaches should be used with the acknowledgment of high uncertainty inherent to biotech pipelines; model inputs materially change outputs for the ibrx stock price.
Corporate governance and management
Leadership and governance influence investor confidence, which in turn affects the ibrx stock price. Key executive profiles to monitor include the CEO, head of clinical development, and CFO. Board composition, governance practices and any sudden leadership change may move sentiment and the ibrx stock price.
Investors should review proxy statements and press releases to stay updated on executive hires, departures and board changes.
Legal, regulatory and shareholder matters
Legal proceedings, shareholder suits and regulatory inquiries can be material to the ibrx stock price. Public filings and press statements disclose any notable litigation or investigations; investors should monitor SEC filings and company announcements for such matters.
When investigating potential impacts on the ibrx stock price, consider: the magnitude of alleged damages, whether the matter is insured, and the expected timeline for resolution.
Recent news and notable headlines
As of Jan. 20, 2026, according to Benzinga, recent headlines that materially affected the ibrx stock price included:
- FDA Type B meeting feedback regarding ImmunityBio’s supplemental BLA (sBLA) for Anktiva in papillary NMIBC, with the company planning to submit additional information within 30 days and the agency not requiring a new clinical trial for resubmission.
- Publication and presentation of updated QUILT-3.032 trial data showing robust disease-specific survival and cystectomy avoidance rates over multiple years.
- Enrollment progress in the registrational QUILT-2.005 randomized trial exceeded internal expectations and was reported to be over 85% complete, with full enrollment anticipated by Q2 2026.
- Preliminary net product revenue for Anktiva of approximately $113 million for fiscal 2025 and a Q4 2025 revenue figure of about $38.3 million, representing substantial year-over-year growth.
These items coincided with a surge in the ibrx stock price and unusually high trading volume. Benzinga reported session volume of approximately 178.91 million trades vs. an average volume near 15.9 million at the time of the move, reflecting intense intraday activity and interest.
Analyst commentary accompanying these developments included brokerages maintaining positive ratings and revising targets, which were cited in market coverage alongside technical indicators suggesting short-term overbought conditions (e.g., elevated RSI values).
How to check the current IBRX stock price
To view the current ibrx stock price and related data:
- Use your brokerage or trading platform for live executable quotes; for custody and trading services, Bitget’s market interface and Bitget Wallet provide integrated access and educational resources.
- Check major market-data aggregators and the NASDAQ market-activity page for consolidated trade data and official exchange information.
- For research and commentary, consult analyst notes on Seeking Alpha, aggregated key stats on MarketWatch and real-time news on CNBC and CNN Markets.
- Community sentiment can be monitored on StockTwits and similar discussion forums, but treat social sentiment as supplementary to verified filings and official releases.
When reading quotes, note the timestamp, whether the price is regular-session or extended-hours, and whether the feed is delayed. Executed prices (what a buyer or seller actually receives) may differ from displayed indicative prices on delayed public pages.
See also
- Immunotherapy companies
- Biotech sector ETFs and indices
- Anktiva (nogapendekin alfa inbakicept) clinical programs
- Tickers and companies with comparable focus in oncology immunotherapy
References
- Seeking Alpha — ImmunityBio, Inc. (IBRX) stock page (analysis, news)
- MarketWatch — IBRX stock page and company profile
- StockTwits — IBRX community feed and intraday commentary
- CNBC — IBRX quote and key statistics
- Robinhood — IBRX quote snapshot and market data (platform snapshot)
- Nasdaq — IBRX market-activity and real-time pages
- CNN Markets — IBRX quote and news aggregation
- Benzinga coverage referenced for Jan. 20, 2026 reporting on FDA meeting feedback, trial data, revenue and intraday price action
(Reporting date example: As of Jan. 20, 2026, according to Benzinga, ImmunityBio disclosed FDA feedback and published trial and preliminary revenue figures that coincided with a sharp rise in the ibrx stock price.)
External links
- Company investor relations page (ImmunityBio investor relations)
- SEC EDGAR filings for ImmunityBio (quarterly and annual reports, 8-Ks)
- Market-data providers: NASDAQ market pages, MarketWatch, Seeking Alpha, CNBC
For access to live market data and secure trade execution, users can explore Bitget’s market pages and Bitget Wallet for custody and portfolio management.
Disclosure: This article is informational and does not constitute investment advice. All facts cited are drawn from public market-data sources and company disclosures; readers should consult official filings and their own brokers or financial advisors for decisions related to buying or selling shares of IBRX.
The ibrx stock price headline and updates are driven by clinical news, regulatory actions, revenue reports and liquidity. Monitoring the ibrx stock price across multiple reliable sources helps confirm the latest executable price and trading conditions. For real-time execution and custody, consider Bitget’s trading platform and Bitget Wallet.
Key takeaways for following the ibrx stock price: - Watch clinical and regulatory timelines for Anktiva. - Monitor quarterly revenue and enrollment updates. - Track volume and short interest alongside institutional filings. - Use real-time broker feeds or Bitget market pages for tradeable prices.
To recap, the ibrx stock price reflects both company fundamentals and binary clinical/regulatory events that are common in the biotech sector. Historical price action shows large intraday moves tied to high-visibility announcements such as FDA feedback and trial readouts. Stay current with company press releases, SEC filings and reputable market-data sources to interpret changes in the ibrx stock price.
